10.1038/s41591-019-0628-7 - Clinical efficacy and biomarker analy...

This document has been corrected

Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial

Published Online: 2019-11-?

Journal: Nature Medicine•Publisher: Springer Science and Business Media LLC

Authors: Aaron Prendergast•Alain Ravaud•Albert Font Pous•Alejo Rodriguez-Vida•Andrew Protheroe•Bernadett Szabados•Cristina Suarez•Daniel Castellano•Denis Maillet•Diana Stanoeva•Gwenaelle Gravis•Ignacio Duran•Joy S. Tea•Kelly Mousa•Maria Jose Mendez•Mark Kockx•Mark Linch•Michiel S. Van Der Heijden•Pieter-Jan van Dam•Romain Banchereau•Sanjeev Mariathasan•Simon J. Crabb•Sofie Daelemans•Thomas Powles•Urbano Anido Herranz

This document has been corrected

Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial

Published Online: 2019-11-?

Journal: Nature Medicine

NOW

2023-03-21•Correction

Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial

10.1038/s41591-023-02312-9